Identifying markers for personalized treatment in chronic lymphocytic leukemia
Official title: Predictive markers for personalized therapy in chronic lymphocytic leukemia
Funded at Massachusetts General Hospital · NIH-11058432 · Data updated 2026-11-12
This study is looking for ways to find special markers in people with chronic lymphocytic leukemia (CLL) that can help doctors create more personalized and effective treatments just for you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $285,931 |
| NIH project number | 5K08CA270202-03 |
| Project ID | NIH-11058432 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic lymphocytic leukemia, particularly those with specific genetic markers.
✕Less likely to help
Patients with other types of leukemia or those who do not have chronic lymphocytic leukemia may not benefit from this research.
What this research studies
This research focuses on developing predictive markers that can help tailor personalized therapies for patients with chronic lymphocytic leukemia (CLL). By identifying specific biomarkers, the goal is to enhance treatment effectiveness and improve patient outcomes. The research involves advanced techniques in biomarker assay development and biostatistics, ensuring that the findings can be translated into clinical practice. Patients may benefit from more targeted therapies that are better suited to their individual disease profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with chronic lymphocytic leukemia.
How similar studies have gone: Previous research has shown promise in developing personalized therapies based on biomarkers in similar conditions, indicating a potential for success in this approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Soumerai, Jacob — Massachusetts General Hospital
- Study coordinator: Soumerai, Jacob
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.